Buchumschlag

Case report: a novel high-dose intravenous immunoglobulin preparation for the treatment of severe pemphigus vulgaris failing standard therapy

Pemphigus vulgaris (PV) is a severe autoimmune bullous dermatosis that is characterized by autoantibodies against epidermal adhesion proteins causing painful mucosal and skin blistering. Standard treatments for PV include corticosteroids, steroid-sparing immunosuppressants, or intravenous monoclonal...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Hauptverfasser: Wiedenmayer, Nadine (VerfasserIn) , Hogrefe, Katharina (VerfasserIn) , Mihalceanu, Silvia (VerfasserIn) , Winkler, Julia K. (VerfasserIn) , Enk, Alexander (VerfasserIn)
Dokumenttyp: Article (Journal)
Sprache:Englisch
Veröffentlicht: December 2024
In: The journal of dermatology
Year: 2024, Jahrgang: 51, Heft: 12, Pages: 1665-1668
ISSN:1346-8138
DOI:10.1111/1346-8138.17475
Online-Zugang:Verlag, kostenfrei, Volltext: https://doi.org/10.1111/1346-8138.17475
Verlag, kostenfrei, Volltext: https://onlinelibrary.wiley.com/doi/abs/10.1111/1346-8138.17475
Volltext
Verfasserangaben:Nadine Wiedenmayer, Katharina Hogrefe, Silvia Mihalceanu, Julia K. Winkler, Alexander H. Enk (Department of Dermatology, University Hospital Heidelberg)
Beschreibung
Zusammenfassung:Pemphigus vulgaris (PV) is a severe autoimmune bullous dermatosis that is characterized by autoantibodies against epidermal adhesion proteins causing painful mucosal and skin blistering. Standard treatments for PV include corticosteroids, steroid-sparing immunosuppressants, or intravenous monoclonal anti-CD20-antibody therapy. The European guidelines suggest high-dose intravenous immunoglobulin (IVIg) therapy as a promising approach for severe or treatment-resistant cases. We report on a 65-year-old woman with severe and recurrent disease who achieved long-term disease stabilization with IVIg treatment. Because of recurrent fatigue and headache, the patient was switched to an alternative IVIg preparation with a novel manufacturing process, thus ensuring high purity and better tolerability. We observed excellent efficacy, yet side effects remained largely unchanged. Further studies are necessary to evaluate the long-term efficacy and tolerability of this new IVIg preparation.
Beschreibung:Gesehen am 26.02.2025
Beschreibung:Online Resource
ISSN:1346-8138
DOI:10.1111/1346-8138.17475

Ähnliche Einträge